Results 31 to 40 of about 3,791 (213)

In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. [PDF]

PLoS ONE, 2017
BACKGROUND:Absorbed doses for α-emitters are different from those for β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense energy deposition over a relatively short path length near the point of emission ...
Ho Sze Chan, Erik de Blois, Alfred Morgenstern, Frank Bruchertseifer, Marion de Jong, Wouter Breeman, Mark Konijnenberg   +6 more
doaj   +1 more source

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Frontiers in Endocrinology, 2021
Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share
Elena María Vida Navas, Alberto Martínez Lorca, Aintzane Sancho Gutiérrez, Lucia Sanz Gómez, Teresa Navarro Martínez, Enrique Grande Pulido, Alfredo Carrato Mena, Pablo Gajate Borau   +7 more
doaj   +1 more source

Impact of Using Corticosteroid Prophylaxis to Prevent Tumor Flare Reactions During ¹⁷⁷Lu-DOTATATE Treatment in Patients with Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Simple Summary 177Lu-DOTATATE has changed the treatment landscape for patients with gastroenteropancreatic neuroendocrine tumors. As with all therapies, side effects are inevitable.
Cass AS, Skotte E, Wheless MC, Stockton S, Ramirez RA.   +4 more
europepmc   +2 more sources

Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation

Case Reports in Oncology, 2023
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine.
Anke Kröcher, Gunnar Folprecht, Robert Winzer, Mildred Sergon, Martin Bornhäuser, Jörg Kotzerke, Claudia Brogsitter   +6 more
doaj   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

New England Journal of Medicine, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first‐line somatostatin analogue therapy have limited therapeutic options.
J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, James C. Yao, B. Chasen, E. Mittra, P. Kunz, M. Kulke, H. Jacene, D. Bushnell, T. O'Dorisio, R. Baum, H. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Sierra, P. Santoro, T. Thévenet, J. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning   +34 more
semanticscholar   +1 more source

Evaluating the prognostic significance of the pre-treatment neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios in ¹⁷⁷Lu-DOTATATE PRRT treated patients with advanced metastatic neuroendocrine tumors. [PDF]

Endocrine
This study aimed to investigate the role of pre-treatment neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) in the prognosis assessment of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) treated patients with ...
Padwal MK, Nazar AK, Parghane RV, Basu S, Basu B.   +4 more
europepmc   +2 more sources

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

EJNMMI Research, 2022
Background Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [177Lu]Lu-HA-DOTATATE uptake in tumors and organs.
Hinke Siebinga, Chayenne H. A. M. Veerman, Linda de Wit-van der Veen, Marcel P. M. Stokkel, Jeroen J. M. A. Hendrikx, Else A. Aalbersberg   +5 more
doaj   +1 more source

Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study

Journal of Nuclear Medicine, 2023
Visual Abstract Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients.
Magdalena Mileva, Gwennaëlle Marin, H. Levillain, C. Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, A. Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, B. Vanderlinden, M. Paesmans, L. Ameye, G. Critchi, Loubna Taraji-Schiltz, C. Velghe, Z. Wimana, Maria Bali, A. Hendlisz, P. Flamen, I. Karfis   +21 more
semanticscholar   +1 more source

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates

EJNMMI Physics, 2021
Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelled somatostatin analogues is a procedure with multiple steps.
Peter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, Peter Iversen, Anne Kirstine Arveschoug   +4 more
doaj   +1 more source

Research Progress of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety

Journal of Isotopes, 2022
Neuroendocrine tumors (NENs) are rare tumors arising from neuroendocrine cells distributed throughout the body. 177Lu-DOTATATE has been shown to significantly prolong the progression-free survival of patients, and has been widely used abroad.
MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao
doaj